BCT Press Release
Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}

Press Release

908 Devices and Terumo Blood and Cell Technologies Collaborate to Add On-line Analytics to Quantum Flex Cell Expansion System

Automation combined with on-line monitoring during the cell expansion step can bring cell therapy manufacturing efficiencies and enable increased patient accessibility and safety


BOSTON, Mass. and LAKEWOOD, Colo. – 908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, and medical technology company Terumo Blood and Cell Technologies (Terumo BCT) announced a collaboration to enable on-line monitoring of critical process parameters in Terumo BCT's Quantum Flex Cell Expansion System. The combination of the companies' automation technologies will help advance the development of life-saving cell and gene therapies by providing insights into and control of one of the largest components of cell therapy development and manufacturing.

Cell and gene therapy developers are increasingly looking to automation to improve manufacturing efficiency, simplify workflows and reduce costs. But quality control today requires having expert staff spending hours on clean room floors to perform manual tasks without error or contamination instead of responding only as needed when issues arise.

908 Devices is introducing MAVEN, its on-line glucose and lactate analyzer, to Terumo BCT's Quantum Flex to provide cell and gene therapy development customers with the ability to monitor and control key process parameters in cell cultures without having to enter the clean room and perform manual sampling. This helps reduce the risk of contamination, save operator time and improve process understanding.

"We are proud to be working with a leading cell therapy technologies innovator to meet the next level of process integration in biopharma," said Kevin J. Knopp, CEO and co-founder of 908 Devices. "We are committed to providing devices that enable scientists to gain insights that reduce costs and accelerate progress."

Terumo BCT's Quantum Flex Cell Expansion System is an automated and functionally closed system purpose-built to meet the needs of cell therapy developers throughout their commercialization journey, from process development to clinical manufacturing. Quantum Flex helps lower the risk of contamination and enables reproducibility and process scale. It is compatible with a range of suspension cells, adherent cells, viral vectors and exosomes.

"Combining our Quantum Flex platform with 908 Devices' on-line monitoring will help cell therapy manufacturers reduce time-consuming manual steps that increase manufacturing costs and risks," said Kathie Schneider, Director, Global Commercial Lead, Cell Therapy Technologies at Terumo BCT. "We continue to collaborate with industry experts to further enhance our solution offering to solve industry challenges."

About 908 Devices
​908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company's devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning. ​

About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions.

Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers, plasma collection facilities and private medical practices. Our customers are based in over 150 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.

We have global headquarters in Lakewood, Colo., U.S.A., along with five regional headquarters, eight manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology. 

Forward-Looking Statements for 908 Devices
This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company's products. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management's current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under "Risk Factors" and elsewhere in the Company's filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in the Company's annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.​


{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }} {{'SEARCH_MODAL_ENLABEL' | translate }}
{{$index+1}}. {{s.label}}